Last $9.26 USD
Change Today +0.18 / 1.98%
Volume 113.0K
DSCI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

derma sciences inc (DSCI) Snapshot

Open
$9.10
Previous Close
$9.08
Day High
$9.43
Day Low
$9.10
52 Week High
02/24/14 - $15.51
52 Week Low
09/16/14 - $7.88
Market Cap
233.8M
Average Volume 10 Days
105.9K
EPS TTM
$-1.56
Shares Outstanding
25.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DERMA SCIENCES INC (DSCI)

Related News

No related news articles were found.

derma sciences inc (DSCI) Related Businessweek News

No Related Businessweek News Found

derma sciences inc (DSCI) Details

Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. It operates in three segments: Advanced Wound Care, Traditional Wound Care, and Pharmaceutical Wound Care. The company offers Medihoney dressings for managing non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; TCC-EZ total contact cast system for patients with diabetic foot ulcers; AMNIOEXCEL for tissue repair and regeneration; and AMNIOMATRIX, which is used as a wound covering in the treatment of localized tissue defects. It also provides Xtrasorb dressings that convert fluid within the dressings to a gel and lock the exudates into the dressings; Bioguard dressings for prophylactic use in the prevention of hospital or community acquired infections through wound sites; ALGICELL AG antimicrobial dressings; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and DERMAGRAN products. In addition, the company offers gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices; adhesive bandages and related first aid products; wound closure strips, nasal tube fasteners, and catheter fasteners; and general purpose and specialized skin care products. Further, it develops DSC127, an angiotensin analog that is in Phase III clinical trials for the treatment of diabetic foot ulcers and preclinical testing for scar reduction. The company sells its products to various health care providers, such as wound care centers, extended care facilities, acute care facilities, home health care agencies, physicians’ offices, nursing homes, hospitals, and clinics through direct sales and manufacturers’ representatives, independent distributors, and retail channels primarily in the United States, Canada, and the United Kingdom. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.

258 Employees
Last Reported Date: 03/13/14
Founded in 1984

derma sciences inc (DSCI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $450.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $260.0K
Executive Vice President of Operations and Ge...
Total Annual Compensation: $252.4K
Group President of Advanced Wound Care and Ph...
Total Annual Compensation: $280.0K
Group President of Traditional Wound Care and...
Total Annual Compensation: $240.0K
Compensation as of Fiscal Year 2013.

derma sciences inc (DSCI) Key Developments

Derma Sciences Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 03:00 PM

Derma Sciences Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 03:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Edward Joseph Quilty, Chairman, Chief Executive Officer and President.

Derma Sciences Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 02:45 PM

Derma Sciences Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 02:45 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: John E. Yetter, Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Finance.

Derma Sciences Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Sales Guidance for the Year 2014

Derma Sciences Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company recorded net sales of $20,169,129 compared to $22,080,434 for the same period a year ago. Operating loss was $11,097,631 compared to $5,387,254 for the same period a year ago. Loss before income taxes was $11,262,321 compared to $5,226,518 for the same period a year ago. Net loss was $11,247,748 compared to $4,948,763 for the same period a year ago. Net loss per basic and diluted common share was $0.45 compared to $0.29 for the same period a year ago. The increase in net loss was principally due to the decrease in gross profit and higher operating expenses. For the nine months, the company reported net sales were $60,872,388 compared to $59,018,241 for the same period a year ago. Operating loss was $30,570,500 common share $18,920,847 for the same period a year ago. Loss before income taxes was $30,462,889 compared to $18,832,184 for the same period a year ago. Net loss was $30,204,565 common share $18,538,215 for the same period a year ago. Net loss per basic and diluted common share was $1.24 compared to $1.09 for the same period a year ago. The company expected 2014 net sales will be approximately $85.0 million, representing growth of 6.6% compared with 2013 net sales with AWC growth of approximately 13%. This compares with previous guidance for net sales to be approximately $86.0 million and AWC growth to be approximately 20%. The company now expects TWC growth to be 0% to 2%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCI:US $9.26 USD +0.18

DSCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliqua Inc $4.09 USD +0.13
BioLargo Inc $0.35 USD -0.10
Integra LifeSciences Holdings Corp $53.90 USD +0.22
SANUWAVE Health Inc $0.13 USD +0.05
Smith & Nephew PLC 1,191 GBp +18.00
View Industry Companies
 

Industry Analysis

DSCI

Industry Average

Valuation DSCI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DERMA SCIENCES INC, please visit www.dermasciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.